Cookies are essential for the operation of our website. By using our website, you agree to the use of cookies.
This website uses cookies to improve and personalize content, and for tracking and analytics. By clicking "Accept All Cookies", you are providing consent for Exelixis to collect and retain personal data for Exelixis to optimize the use of this website. You can learn more about Exelixis' use of cookies by reviewing Exelixis' Privacy Statement.
Reject Nonessential Cookies Accept All Cookies
Skip to main content

Disable motion

Explore
Our Pipeline

We are building a robust and diverse oncology pipeline through discovery and collaboration efforts. Our focus is on targets with novel and promising MOAs and next-generation approaches, including both small molecules and biologics.

XB002: TF-Targeted ADC

A rationally designed, next-generation tissue factor (TF)–targeted antibody-drug conjugate (ADC) using a novel auristatin-linker payload that inhibits cell division by blocking tubulin polymerization.
Click to go to Resource

XL092: TKI

A next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET, the TAM kinases AXL and MER, and other kinases implicated in the growth and spread of cancer.
Click to go to Resource

XL102: CDK7 Inhibitor

A potent, selective, and orally bioavailable small molecule cyclin-dependent kinase 7 (CDK7) inhibitor, an important regulator of cell cycle progression and gene transcription, with overexpression observed in multiple cancers.
Click to go to Resource

XL114: CBM Pathway Inhibitor

A novel orally bioavailable inhibitor of the CARD11-BCL10-MALT1 (CBM) signaling pathway, which promotes lymphocyte proliferation and survival.
Click to go to Resource
Molecular structures shown are artistic renderings